{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Clinical+estrogen+therapy&page=2", "query": { "intervention": "Clinical estrogen therapy", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 89, "total_pages": 9, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Clinical+estrogen+therapy&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Clinical+estrogen+therapy&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-03T17:56:09.881Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04719273", "title": "Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Refractory Endometrial Adenocarcinoma", "Refractory Endometrial Carcinoma", "Refractory Endometrial Clear Cell Adenocarcinoma", "Refractory Endometrial Endometrioid Adenocarcinoma", "Refractory Endometrial Mixed Cell Adenocarcinoma", "Refractory Endometrial Serous Adenocarcinoma", "Refractory Endometrial Undifferentiated Carcinoma" ], "interventions": [ { "name": "Extended-release Onapristone", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Estrogen Receptor Positive (Positive Estrogen Receptor; ESR Positive; ESR1 Positive; ER Positive; Estrogen Receptor Alpha Positive)", "type": "DIAGNOSTIC_TEST" }, { "name": "Progesterone Receptor Positive ( PGR Positive; PR Positive)", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "OTHER", "DIAGNOSTIC_TEST" ], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 14, "start_date": "2021-01-28", "completion_date": "2025-12-17", "has_results": true, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-10-03T17:56:09.881Z", "location_count": 2, "location_summary": "Abington, Pennsylvania • Philadelphia, Pennsylvania", "locations": [ { "city": "Abington", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04719273" }, { "nct_id": "NCT04247126", "title": "A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Breast Cancer", "Small-cell Lung Cancer", "Pancreatic Cancer" ], "interventions": [ { "name": "SY-5609", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Syros Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 105, "start_date": "2020-01-23", "completion_date": "2023-03-30", "has_results": false, "last_update_posted_date": "2023-10-27", "last_synced_at": "2026-10-03T17:56:09.881Z", "location_count": 16, "location_summary": "Gilbert, Arizona • Los Angeles, California • Orlando, Florida + 11 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04247126" }, { "nct_id": "NCT05080842", "title": "A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "AC682", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Accutar Biotechnology Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2021-11-12", "completion_date": "2024-04-04", "has_results": false, "last_update_posted_date": "2025-02-13", "last_synced_at": "2026-10-03T17:56:09.881Z", "location_count": 5, "location_summary": "Denver, Colorado • Orlando, Florida • Sarasota, Florida + 2 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05080842" }, { "nct_id": "NCT07340541", "title": "Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Metastatic Breast Cancer", "Triple Negative Breast Cancer", "Estrogen-receptor-positive Breast Cancer", "Hormone Receptor Negative Breast Carcinoma" ], "interventions": [ { "name": "SERD* + abemaciclib", "type": "DRUG" }, { "name": "SERD* + everolimus", "type": "DRUG" }, { "name": "SERD* + everolimus or capecitabine", "type": "DRUG" }, { "name": "SOC", "type": "DRUG" }, { "name": "Antiandrogen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 700, "start_date": "2026-02-16", "completion_date": "2031-06-02", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-03T17:56:09.881Z", "location_count": 6, "location_summary": "New Haven, Connecticut • Baltimore, Maryland • Rochester, Minnesota + 3 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07340541" }, { "nct_id": "NCT00265759", "title": "Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "anastrozole", "type": "DRUG" }, { "name": "exemestane", "type": "DRUG" }, { "name": "letrozole", "type": "DRUG" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 622, "start_date": "2006-01", "completion_date": "2019-11-27", "has_results": true, "last_update_posted_date": "2025-04-23", "last_synced_at": "2026-10-03T17:56:09.881Z", "location_count": 3, "location_summary": "St Louis, Missouri • Houston, Texas • Laredo, Texas", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Houston", "state": "Texas" }, { "city": "Laredo", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00265759" }, { "nct_id": "NCT00580112", "title": "An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Trabectedin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 127, "start_date": "2007-06", "completion_date": "2011-08", "has_results": false, "last_update_posted_date": "2014-02-25", "last_synced_at": "2026-10-03T17:56:09.881Z", "location_count": 21, "location_summary": "Sedona, Arizona • Denver, Colorado • Torrington, Connecticut + 18 more", "locations": [ { "city": "Sedona", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Torrington", "state": "Connecticut" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Westminster", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00580112" }, { "nct_id": "NCT03281902", "title": "Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Advanced Breast Carcinoma", "Locally Advanced Breast Carcinoma", "Metastatic Breast Carcinoma", "Recurrent Breast Carcinoma", "Stage III Breast Cancer AJCC v7", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIC Breast Cancer AJCC v7", "Stage IV Breast Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 68, "start_date": "2017-11-13", "completion_date": "2028-03-04", "has_results": false, "last_update_posted_date": "2026-06-09", "last_synced_at": "2026-10-03T17:56:09.881Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03281902" }, { "nct_id": "NCT00503841", "title": "Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "biopsy", "type": "PROCEDURE" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "18 Years to 120 Years · Female only" }, "enrollment_count": 44, "start_date": "2007-12", "completion_date": "2010-05", "has_results": true, "last_update_posted_date": "2019-04-30", "last_synced_at": "2026-10-03T17:56:09.881Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00503841" }, { "nct_id": "NCT00417885", "title": "A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "exemestane", "type": "DRUG" }, { "name": "sunitinib malate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 6, "start_date": "2007-06", "completion_date": "2009-07", "has_results": true, "last_update_posted_date": "2010-09-21", "last_synced_at": "2026-10-03T17:56:09.881Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00417885" }, { "nct_id": "NCT06067503", "title": "Biomarkers to Detect Endocrine Therapy Resistance", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Cancer", "Breast Cancer", "Lobular Breast Carcinoma" ], "interventions": [ { "name": "18F-fluorofuranylnorprogesterone", "type": "DRUG" }, { "name": "Liquid Biopsy", "type": "DEVICE" }, { "name": "Positron Emission Tomography/Computed Tomography", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2024-04-30", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-03T17:56:09.881Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT06067503" } ] }